Literature DB >> 31114023

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.

Tania Jain1, Craig S Sauter1,2, Gunjan L Shah1,2, Molly A Maloy1, Jason Chan1, Michael Scordo1,2, Scott T Avecilla3, Yakup Batlevi1, Parastoo B Dahi1,2, Connie W Batlevi2,4, M Lia Palomba2,4, Sergio A Giralt1,2, Miguel-Angel Perales5,6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31114023      PMCID: PMC8224498          DOI: 10.1038/s41375-019-0476-y

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  17 in total

1.  Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

Authors:  Arnab Ghosh; Melody Smith; Scott E James; Marco L Davila; Enrico Velardi; Kimon V Argyropoulos; Gertrude Gunset; Fabiana Perna; Fabiana M Kreines; Emily R Levy; Sophie Lieberman; Hillary V Jay; Andrea Z Tuckett; Johannes L Zakrzewski; Lisa Tan; Lauren F Young; Kate Takvorian; Jarrod A Dudakov; Robert R Jenq; Alan M Hanash; Ana Carolina F Motta; George F Murphy; Chen Liu; Andrea Schietinger; Michel Sadelain; Marcel R M van den Brink
Journal:  Nat Med       Date:  2017-01-09       Impact factor: 53.440

Review 2.  Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.

Authors:  Miguel-Angel Perales; Partow Kebriaei; Leslie S Kean; Michel Sadelain
Journal:  Biol Blood Marrow Transplant       Date:  2017-10-13       Impact factor: 5.742

3.  Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Authors:  Stephen J Schuster; Jakub Svoboda; Elise A Chong; Sunita D Nasta; Anthony R Mato; Özlem Anak; Jennifer L Brogdon; Iulian Pruteanu-Malinici; Vijay Bhoj; Daniel Landsburg; Mariusz Wasik; Bruce L Levine; Simon F Lacey; Jan J Melenhorst; David L Porter; Carl H June
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

4.  Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

Authors:  David Miklos; Corey S Cutler; Mukta Arora; Edmund K Waller; Madan Jagasia; Iskra Pusic; Mary E Flowers; Aaron C Logan; Ryotaro Nakamura; Bruce R Blazar; Yunfeng Li; Stephen Chang; Indu Lal; Jason Dubovsky; Danelle F James; Lori Styles; Samantha Jaglowski
Journal:  Blood       Date:  2017-09-18       Impact factor: 22.113

5.  The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

Authors:  Alexandre V Hirayama; Jordan Gauthier; Kevin A Hay; Jenna M Voutsinas; Qian Wu; Ted Gooley; Daniel Li; Sindhu Cherian; Xueyan Chen; Barbara S Pender; Reed M Hawkins; Aesha Vakil; Rachel N Steinmetz; Utkarsh H Acharya; Ryan D Cassaday; Aude G Chapuis; Tejaswini M Dhawale; Paul C Hendrie; Hans-Peter Kiem; Ryan C Lynch; Jorge Ramos; Mazyar Shadman; Brian G Till; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2019-02-19       Impact factor: 22.113

6.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

7.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Authors:  Joseph A Fraietta; Kyle A Beckwith; Prachi R Patel; Marco Ruella; Zhaohui Zheng; David M Barrett; Simon F Lacey; Jan Joseph Melenhorst; Shannon E McGettigan; Danielle R Cook; Changfeng Zhang; Jun Xu; Priscilla Do; Jessica Hulitt; Sagar B Kudchodkar; Alexandria P Cogdill; Saar Gill; David L Porter; Jennifer A Woyach; Meixiao Long; Amy J Johnson; Kami Maddocks; Natarajan Muthusamy; Bruce L Levine; Carl H June; John C Byrd; Marcela V Maus
Journal:  Blood       Date:  2016-01-26       Impact factor: 22.113

8.  Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.

Authors:  Elad Jacoby; Yinmeng Yang; Haiying Qin; Christopher D Chien; James N Kochenderfer; Terry J Fry
Journal:  Blood       Date:  2015-12-11       Impact factor: 22.113

Review 9.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Authors:  Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-25       Impact factor: 5.742

10.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

Authors:  Conrad Russell Y Cruz; Kenneth P Micklethwaite; Barbara Savoldo; Carlos A Ramos; Sharon Lam; Stephanie Ku; Oumar Diouf; Enli Liu; A John Barrett; Sawa Ito; Elizabeth J Shpall; Robert A Krance; Rammurti T Kamble; George Carrum; Chitra M Hosing; Adrian P Gee; Zhuyong Mei; Bambi J Grilley; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Catherine M Bollard; Gianpietro Dotti
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

View more
  12 in total

Review 1.  Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?

Authors:  Peter Dreger; Timothy S Fenske; Silvia Montoto; Marcelo C Pasquini; Anna Sureda; Mehdi Hamadani
Journal:  Biol Blood Marrow Transplant       Date:  2020-01-07       Impact factor: 5.742

Review 2.  Sequencing of Novel Therapies for Mantle Cell Lymphoma.

Authors:  Jason T Romancik; Jonathon B Cohen
Journal:  Curr Treat Options Oncol       Date:  2021-11-23

Review 3.  Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.

Authors:  Moritz Ernst; Annika Oeser; Burcu Besiroglu; Julia Caro-Valenzuela; Mohamed Abd El Aziz; Ina Monsef; Peter Borchmann; Lise J Estcourt; Nicole Skoetz; Marius Goldkuhle
Journal:  Cochrane Database Syst Rev       Date:  2021-09-13

4.  Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.

Authors:  Tania Jain; Andrea Knezevic; Martina Pennisi; Yunxin Chen; Josel D Ruiz; Terence J Purdon; Sean M Devlin; Melody Smith; Gunjan L Shah; Elizabeth Halton; Claudia Diamonte; Michael Scordo; Craig S Sauter; Elena Mead; Bianca D Santomasso; M Lia Palomba; Connie W Batlevi; Molly A Maloy; Sergio Giralt; Eric Smith; Renier Brentjens; Jae H Park; Miguel-Angel Perales; Sham Mailankody
Journal:  Blood Adv       Date:  2020-08-11

5.  Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.

Authors:  Jun Meng; XiaoQin Wu; Zhen Sun; RenDe Xun; MengSi Liu; Rui Hu; JianChao Huang
Journal:  Front Oncol       Date:  2021-07-26       Impact factor: 6.244

Review 6.  The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice.

Authors:  Marco Cerrano; Marco Ruella; Miguel-Angel Perales; Candida Vitale; Danilo Giuseppe Faraci; Luisa Giaccone; Marta Coscia; Molly Maloy; Miriam Sanchez-Escamilla; Hesham Elsabah; Afraa Fadul; Enrico Maffini; Gianfranco Pittari; Benedetto Bruno
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

Review 7.  Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?

Authors:  Scott R Goldsmith; Armin Ghobadi; John F DiPersio
Journal:  Front Oncol       Date:  2020-12-22       Impact factor: 6.244

Review 8.  Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.

Authors:  Jennifer Marvin-Peek; Bipin N Savani; Oluwole O Olalekan; Bhagirathbhai Dholaria
Journal:  Cancers (Basel)       Date:  2022-01-19       Impact factor: 6.639

9.  Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.

Authors:  Victoria Gutgarts; Tania Jain; Junting Zheng; Molly A Maloy; Josel D Ruiz; Martina Pennisi; Edgar A Jaimes; Miguel-Angel Perales; Jaffer Sathick
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-20       Impact factor: 5.742

10.  Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.

Authors:  XiaoQin Wu; XinYue Zhang; RenDe Xun; MengSi Liu; Zhen Sun; JianChao Huang
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.